Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.998 EUR | -0.64% | -2.71% | +35.14% |
07/05 | AstraZeneca target raised; Antofagasta lowered | AN |
03/05 | AIB GROUP : Stronger revenue growth and a benign cost of risk |
Sales 2024 * | 4.56B 4.89B 409B | Sales 2025 * | 4.34B 4.65B 390B | Capitalization | 12.34B 13.24B 1,108B |
---|---|---|---|---|---|
Net income 2024 * | 1.76B 1.89B 158B | Net income 2025 * | 1.56B 1.67B 140B | EV / Sales 2024 * | 2.71 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
7.11
x | P/E ratio 2025 * |
7.4
x | Employees | - |
Yield 2024 * |
5.89% | Yield 2025 * |
6.25% | Free-Float | 68.01% |
Latest transcript on AIB Group plc
1 week | -2.71% | ||
Current month | -2.71% | ||
1 month | +3.16% | ||
3 months | +15.53% | ||
6 months | +27.21% | ||
Current year | +35.14% |
Managers | Title | Age | Since |
---|---|---|---|
Colin Hunt
CEO | Chief Executive Officer | 54 | 01/16/01 |
Donal Galvin
DFI | Director of Finance/CFO | 50 | 01/13/01 |
Graham Fagan
CTO | Chief Tech/Sci/R&D Officer | - | 19/23/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fergal O’Dwyer
BRD | Director/Board Member | 64 | 22/21/22 |
James Pettigrew
CHM | Chairman | 65 | 28/21/28 |
Brendan McDonagh
BRD | Director/Board Member | 66 | 27/16/27 |
Date | Price | Change |
---|---|---|
11/24/11 | 4.978 | -1.03% |
10/24/10 | 5.03 | -0.59% |
07/24/07 | 5.06 | +1.40% |
06/24/06 | 4.99 | +0.32% |
05/24/05 | 4.974 | -3.70% |
Delayed Quote Börse Stuttgart, June 11, 2024 at 02:00 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.35% | 573B | |
+17.82% | 310B | |
+14.14% | 254B | |
+19.14% | 184B | |
+24.83% | 172B | |
+6.67% | 163B | |
+9.11% | 150B | |
-8.45% | 142B | |
+11.74% | 139B |
- Stock Market
- Equities
- A5G Stock
- A5G Stock